Loading...

KYMR KYMERA THERAPEUTICS INC US FDA Inspections 8-K Filing

KYMR

KYMR

KYMERA THERAPEUTICS INC

(KYMR)

2025 8-K

Bylaw Amendment

Sales Agreement Initiated

Financial Results Announcement

Stock Offering Details

FDA Trial Update

Clinical Trial Results

Financial Results Report

Management Change

Equity Offerings

Product Expansion

Investor Meetings

Product Expansion

Financial Results

Financial Update

Financial Results

Financial Results Announcement

Management Changes

Financial Results Announcement

Appointment of Director

Financial Results Announcement

Underwriting Agreement

Event Announcement

Expansion Plans

Clinical Trial Results

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Shareholders

Appointment of Chief Operat...

Financial Results Announcement

Exposure to Closed Bank

Departure of Directors or C...

Financial Results Announcement

Financial Update

External Links:

On December 8, 2025, Kymera Therapeutics, Inc. held a conference call to discuss the results of its BroADen Phase 1b atopic dermatitis trial for KT-621, an oral STAT6 degrader. This event is significant as it pertains to the development of a new treatment option.

AI Assistant

KYMERA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.